HDAC9 and neoplasm: To this end, HDAC inhibitors MS275 [266], SAHA [267], valproic acid [268], depsipeptide [269], SBHA [270], and LAQ824 [271] have been shown to augment TRAIL responses in various tumor types including prostate cancer, primary myeloid leukemia, melanoma, breast cancer, medulloblastoma, glioblastoma, and CLL.